Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Myopic refraction between -1.00D and -4.50D
Normal break up time of tear film (BUT > 10s)
Astigmatism equal or less than -1.50D
...
Myopic refraction between -1.00D and -4.50D
Normal break up time of tear film (BUT > 10s)
Astigmatism equal or less than -1.50D
Adolescent myopia patients

Exclusion Criteria

Hyperopia
Existence of any ocular diseases except ametropia
Severe dry eye
Hyperopia
Existence of any ocular diseases except ametropia
Severe dry eye

Summary

Conditions
Progressive Myopia
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 10 years and 15 years
Gender
Both males and females

Description

Different lens treatments include normal spectacle lens, orthokeratology, and Myovision (a specially designed spectacle lens commercially available with peripheral defocus controlled as relative myopia). This study is to evaluate the efficacy of these three methods in controlling myopia progression....

Different lens treatments include normal spectacle lens, orthokeratology, and Myovision (a specially designed spectacle lens commercially available with peripheral defocus controlled as relative myopia). This study is to evaluate the efficacy of these three methods in controlling myopia progression. Until now, there is no sufficient clinical evidences to compare different lens treatments.

Inclusion Criteria

Myopic refraction between -1.00D and -4.50D
Normal break up time of tear film (BUT > 10s)
Astigmatism equal or less than -1.50D
...
Myopic refraction between -1.00D and -4.50D
Normal break up time of tear film (BUT > 10s)
Astigmatism equal or less than -1.50D
Adolescent myopia patients

Exclusion Criteria

Hyperopia
Existence of any ocular diseases except ametropia
Severe dry eye
Hyperopia
Existence of any ocular diseases except ametropia
Severe dry eye

Tracking Information

NCT #
NCT02001415
Collaborators
Not Provided
Investigators
  • Principal Investigator: Kai Wang, Dr. Peking University People's Hospital
  • Kai Wang, Dr. Peking University People's Hospital